Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Enzalutamide

FDA-approved product (capsule, oral), marketed as Enzalutamide, Xtandi.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Enzalutamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma
  • Prostate neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anti-androgens
FDA pharmacologic class
Androgen Receptor Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Enzalutamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Enzalutamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Oral MRT-2359 in Selected Cancer Patients

    NCT05546268 · start 2022-10-12

    Registered record
    Registry ID
    NCT05546268
    Conditions
    NSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC With High or Low L-MYC or N-MYC Expression; HR-positive, HER2-negative Breast Cancer; Prostate Cancer
    Interventions
    Oral MRT-2359; Oral MRT-2359; Oral MRT-2359; Oral MRT-2359; Oral MRT-2359; Oral MRT-2359
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2022-10-12
    Completion
    2027-11
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL +4 more
    InterventionOral MRT-2359; Oral MRT-2359; Oral MRT-2359; Oral MRT-2359 +2 more
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Study of ORIC-944 in Patients With Metastatic Prostate Cancer

    NCT05413421 · start 2022-06-01

    Registered record
    Registry ID
    NCT05413421
    Conditions
    Metastatic Prostate Cancer
    Interventions
    ORIC-944; Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets; Apalutamide (Erleada™) 60 mg or 240 mg tablets; Darolutamide (Nubeqa®) 300 mg tablets; Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2022-06-01
    Completion
    2028-04
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Prostate Cancer
    InterventionORIC-944; Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets; Apalutamide (Erleada™) 60 mg or 240 mg tablets; Darolutamide (Nubeqa®) 300 mg tablets +1 more
    PhasePhase 1
    Registry statusRecruiting

  • Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

    NCT05352178 · start 2022-04-20

    Registered record
    Registry ID
    NCT05352178
    Conditions
    Prostate Cancer; Prostate Cancer Recurrent; Prostate Cancer Metastatic; Metastatic Cancer; Oligometastatic Disease; Oligometastasis; Hormone Sensitive Prostate Cancer
    Interventions
    Radiotherapy (SBRT) and/or surgery (metastasectomy); Androgen deprivation therapy; Androgen receptor targeted therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-04-20
    Completion
    2032-04-25
    Enrolment
    873

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Prostate Cancer Recurrent; Prostate Cancer Metastatic; Metastatic Cancer +3 more
    InterventionRadiotherapy (SBRT) and/or surgery (metastasectomy); Androgen deprivation therapy; Androgen receptor targeted therapy
    PhasePhase 3
    Registry statusRecruiting

  • An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings

    NCT05362149 · start 2022-04-04

    Registered record
    Registry ID
    NCT05362149
    Conditions
    Non-metastatic Castration-resistant Prostate Cancer
    Interventions
    Darolutamide (Nubeqa, BAY1841788); Enzalutamide; Apalutamide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-04-04
    Completion
    2023-06-30
    Enrolment
    870

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-metastatic Castration-resistant Prostate Cancer
    InterventionDarolutamide (Nubeqa, BAY1841788); Enzalutamide; Apalutamide
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

    NCT05081193 · start 2022-03-07

    Registered record
    Registry ID
    NCT05081193
    Conditions
    Prostate Cancer; Castration-resistant Prostate Cancer; Metastatic Castration-resistant Prostate Cancer
    Interventions
    Testosterone Undecanoate; Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-03-07
    Completion
    2025-08-04
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Castration-resistant Prostate Cancer; Metastatic Castration-resistant Prostate Cancer
    InterventionTestosterone Undecanoate; Enzalutamide
    PhasePhase 2
    Registry statusCompleted

  • 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

    NCT05204927 · start 2022-02-14

    Registered record
    Registry ID
    NCT05204927
    Conditions
    Metastasis From Malignant Tumor of Prostate
    Interventions
    177Lu-PSMA-I&T; Abiraterone with Prednisone or Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2022-02-14
    Completion
    2029-02
    Enrolment
    439

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastasis From Malignant Tumor of Prostate
    Intervention177Lu-PSMA-I&T; Abiraterone with Prednisone or Enzalutamide
    PhasePhase 3
    Registry statusActive not recruiting

  • FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

    NCT05011188 · start 2022-01-19

    Registered record
    Registry ID
    NCT05011188
    Conditions
    Metastatic Castration-resistant Prostate Cancer; Prostate Cancer
    Interventions
    FOR46; Enzalutamide; Pegfilgrastim; Blood Samples
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2022-01-19
    Completion
    2027-07-31
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer; Prostate Cancer
    InterventionFOR46; Enzalutamide; Pegfilgrastim; Blood Samples
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Search for Predictive Factors of Resistance to Treatment for Metastatic Castration-resistant Prostate Cancer by Studying the Expression of microRNAs

    NCT04662996 · start 2021-06-23

    Registered record
    Registry ID
    NCT04662996
    Conditions
    Prostate Cancer; Resistance, Disease; MicroRNAs
    Interventions
    Blood sample
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-06-23
    Completion
    2023-11-30
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Resistance, Disease; MicroRNAs
    InterventionBlood sample
    PhaseNot applicable
    Registry statusCompleted

  • A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

    NCT04729114 · start 2021-06-14

    Registered record
    Registry ID
    NCT04729114
    Conditions
    Prostate Cancer; Metastatic Castration Resistant Prostate Cancer; Metastatic Castration-sensitive Prostate Cancer
    Interventions
    PRL-02 injection; prednisone; dexamethasone; enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2021-06-14
    Completion
    2029-05-31
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Metastatic Castration Resistant Prostate Cancer; Metastatic Castration-sensitive Prostate Cancer
    InterventionPRL-02 injection; prednisone; dexamethasone; enzalutamide
    PhasePhase 1
    Registry statusRecruiting

  • Study of ORIC-101 in Combination With Enzalutamide

    NCT04033328 · start 2019-10-28

    Registered record
    Registry ID
    NCT04033328
    Conditions
    Prostatic Neoplasms
    Interventions
    ORIC-101; enzalutamide 40 MG oral capsule [Xtandi]
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2019-10-28
    Completion
    2023-12-04
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    InterventionORIC-101; enzalutamide 40 MG oral capsule [Xtandi]
    PhasePhase 1
    Registry statusTerminated

  • The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

    NCT03899467 · start 2019-05-30

    Registered record
    Registry ID
    NCT03899467
    Conditions
    Metastatic Castrate Resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Interventions
    GT0918
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-05-30
    Completion
    2022-09-19
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castrate Resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    InterventionGT0918
    PhasePhase 2
    Registry statusCompleted

  • A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

    NCT03809000 · start 2019-04-15

    Registered record
    Registry ID
    NCT03809000
    Conditions
    Prostate Cancer
    Interventions
    Radiation Therapy; Enzalutamide; Bicalutamide; GnRH analog
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-04-15
    Completion
    2029-09-15
    Enrolment
    188

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionRadiation Therapy; Enzalutamide; Bicalutamide; GnRH analog
    PhasePhase 2
    Registry statusActive not recruiting

  • Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide

    NCT03764540 · start 2019-04-01

    Registered record
    Registry ID
    NCT03764540
    Conditions
    Metastatic Prostate Cancer
    Interventions
    Cabazitaxel plus prednisone; Docetaxel plus prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-04-01
    Completion
    2024-12-31
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Prostate Cancer
    InterventionCabazitaxel plus prednisone; Docetaxel plus prednisone
    PhasePhase 2
    Registry statusTerminated

  • A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

    NCT03811652 · start 2018-12-20

    Registered record
    Registry ID
    NCT03811652
    Conditions
    Non Small Cell Lung Cancer Squamous (NSCLC-Sq); Head and Neck Squamous Cell Carcinoma (HNSCC); Small Cell Lung Cancer (SCLC); Pancreatic Ductal Adenocarcinoma (PDAC); Colorectal Cancer (CRC); Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Interventions
    MEDI7247
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-12-20
    Completion
    2019-12-10
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer Squamous (NSCLC-Sq); Head and Neck Squamous Cell Carcinoma (HNSCC); Small Cell Lung Cancer (SCLC); Pancreatic Ductal Adenocarcinoma (PDAC) +2 more
    InterventionMEDI7247
    PhasePhase 1
    Registry statusCompleted

  • Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

    NCT03753243 · start 2018-12-03

    Registered record
    Registry ID
    NCT03753243
    Conditions
    Prostate Cancer
    Interventions
    Pembrolizumab; Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2018-12-03
    Completion
    2023-04-30
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionPembrolizumab; Enzalutamide
    PhasePhase 2
    Registry statusRecruiting